Tag Archives: Multiple

Potential new CAR-T cell therapy for multiple myeloma

Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet. “CAR-T cell therapy is a type of immunotherapy that involves harnessing the power of a person’s own immune system by engineering… Read More »

FDA Approves Sarclisa (isatuximab-irfc) in Combination with Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

PARIS, March 31, 2021 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three prior lines of therapy. “In the Phase 3 IKEMA study, the addition… Read More »

Homemade Raw Chocolate, Multiple Ways

Not only does homemade chocolate taste delicious, but it’s also a fun activity to do on your own or with family or friends! Adding things like strawberry puree, a shot of espresso, key lime juice, cocoa powder, and vanilla to the base recipe will make a variety of raw chocolates within minutes that are all… Read More »

FDA Approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Multiple Myeloma

FDA Approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Multiple Myeloma Print this page HORSHAM, Pa., May 1, 2020 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved Darzalex Faspro (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab. Darzalex Faspro™ is approved in four regimens… Read More »

FDA Approves Sarclisa (isatuximab-irfc) for Patients with Relapsed Refractory Multiple Myeloma

FDA Approves Sarclisa (isatuximab-irfc) for Patients with Relapsed Refractory Multiple Myeloma Print this page BRIDGEWATER, N.J., March 2, 2020 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least… Read More »

Women with single dose of HPV vaccine gain similar protection as multiple doses

A new study revealed that one dose of the HPV vaccine may prevent infection from the potential cancer-causing virus, according to research published in JAMA Network Open from The University of Texas Health Science Center at Houston (UTHealth). According to the Centers for Disease Control (CDC), 34,800 new cancer diagnoses are linked to human papillomavirus… Read More »